Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Exploratory Clinical Study of the Safety and Efficacy of Anti-CD19/BCMA Chimeric Antigen Receptor NK Cell Injection in the Treatment of IgA Nephropathy

NCT06926985 is registered in ClinicalTrials.gov with Jieyang People's Hospital as lead sponsor.

NCT NCT06926985
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06926985 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Exploratory Clinical Study of the Safety and Efficacy of Anti-CD19/BCMA Chimeric Antigen Receptor NK Cell Injection in the Treatment of IgA Nephropathy
Lead sponsor
Jieyang People's Hospital
Phase
Phase 1
Overall status
Withdrawn
Start date
July 30, 2025
Completion date
April 30, 2027
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

iga nephropathy (igan)